More about

Resistant Hypertension

News
August 21, 2023
1 min watch
Save

VIDEO: Resistant hypertension ‘powerful and potent’ risk factor in women

DANA POINT, Calif. — In this Healio video exclusive, Keith C. Ferdinand, MD, discusses resistant hypertension, which he said “is the most powerful and potent cardiovascular risk factor in women.”

News
July 19, 2023
2 min read
Save

Winter-induced BP spikes coincide with faltering control in aggressively treated patients

Winter-induced elevations in BP were persistent among patients with hypertension despite treatment with up to three classes of antihypertensive medications, with an approximately 7% drop in BP control, researchers reported.

News
June 24, 2023
3 min read
Save

Renal denervation lowers BP regardless of antihypertensive regimen, polypharmacy burden

Renal denervation lowered blood pressure out to 36 months, regardless of baseline antihypertensive class combinations and polypharmacy burden, according to an analysis of the Global SYMPLICITY Registry DEFINE.

News
June 15, 2023
4 min read
Save

Drug-based, device-based approaches can safely treat resistant hypertension

PHILADELPHIA — A variety of pharmacologic and device-based approaches provides hope for effective and safe treatment of resistant hypertension, which can be “tedious but important” to diagnose, according to a speaker.

News
March 02, 2023
2 min read
Save

Renal denervation lowers BP in Black patients with resistant hypertension at 3 years

In Black patients with resistant hypertension, renal denervation was associated with reductions in systolic BP at 3 years, according to new data from the SYMPLICITY HTN-3 trial.

News
February 16, 2023
2 min read
Save

BP reduced out to 9 years after renal denervation for resistant hypertension

There was a sustained reduction in ambulatory BP out to 9 years in patients who underwent renal denervation for resistant hypertension, according to a study published in Hypertension.

News
February 16, 2023
1 min read
Save

BrigHTN

Efficacy and safety of multiple dose strengths of baxdrostat vs. placebo in treatment-resistant hypertension.

News
January 17, 2023
1 min read
Save

FRESH

Efficacy and safety of firibastat vs. placebo in adults with uncontrolled primary hypertension.

News
November 16, 2022
3 min read
Save

Baxdrostat cuts BP in patients with resistant hypertension in phase 2 trial

CHICAGO — Baxdrostat, an aldosterone synthase inhibitor, yielded substantial dose-related decreases in BP in patients with treatment-resistant hypertension, according to results from the phase 2 BrigHtn trial.

News
November 15, 2022
2 min read
Save

Dual endothelin receptor antagonist yields sustained BP lowering in resistant hypertension

CHICAGO — Aprocitentan, a dual endothelin antagonist, was superior to placebo for BP lowering and was well tolerated in patients with resistant hypertension, according to results of the PRECISION trial.

View more